Fangjie Yan
886 Yuhangtang Road, P.R. China
Hangzhou, 310058, China
Hangzhou, 310058, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Mechanisms and management of crizotinib-induced toxicity in non-small cell lung cancer.
Journal: Toxicology letters
Published: September 30, 2025
VCP Promotes Cholangiocarcinoma Development by Mediating BAP1 Ubiquitination-Dependent Degradation.
Journal: Cancer science
Published: October 31, 2024
JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4.
Journal: Biochemical pharmacology
Published: September 30, 2024
UniMap: Type-Level Integration Enhances Biological Preservation and Interpretability in Single-Cell Annotation.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 04, 2024
Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.
Journal: Expert opinion on drug metabolism & toxicology
Published: September 03, 2024
The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.
Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: October 30, 2023
The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma.
Journal: Expert opinion on therapeutic targets
Published: October 15, 2022
SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
Journal: Hepatology (Baltimore, Md.)
Published: November 30, 2021
Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis.
Journal: Journal of medicinal chemistry
Published: June 01, 2021
Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
Journal: Acta pharmaceutica Sinica. B
Published: December 21, 2020
Last Updated: 09/26/2026